Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | ACLY | P53396 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613791 | 0.89 | HSD11B1 (0.67) | HSD11B1ACLYKMT2AALDH1A1GAA | |
| SCHEMBL3617650 | 0.87 | HSD11B1 (0.61) | HSD11B1ACLYKMT2AALDH1A1GAA | |
| SCHEMBL3613235 | 0.83 | MAPT (0.49) | HSD11B1KMT2AALDH1A1MAPK1GAA | |
| SCHEMBL3617537 | 0.81 | HSD11B1 (0.60) | HSD11B1KDM4ECNR1 | |
| SCHEMBL7167125 | 0.79 | HSD11B1 (0.49) | HSD11B1KMT2AALDH1A1GAAKDM4E | |
| SCHEMBL3251122 | 0.76 | HSD11B1 (0.67) | HSD11B1ACLYKMT2AALDH1A1GAA | |
| SCHEMBL5831224 | 0.72 | HSD11B1 (0.55) | HSD11B1KMT2AALDH1A1GAAKDM4E | |
| SCHEMBL5831048 | 0.72 | HSD11B1 (0.59) | HSD11B1ACLYKMT2AALDH1A1MAPK1 | |
| SCHEMBL3622882 | 0.72 | HSD11B1 (0.82) | HSD11B1KMT2AALDH1A1POLB | |
| SCHEMBL5831200 | 0.70 | HSD11B1 (0.60) | HSD11B1KMT2AALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885ACLY 1036/4885KMT2A 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.